Stocks
NewAmsterdam Pharma Company N.V.NAMS
NASDAQHealthcareBiotechnology$20.47
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing obicetrapib, an oral CETP inhibitor for lowering LDL cholesterol, with Phase 3 trials underway. Its focus on a potentially safer, more convenient alternative to existing PCSK9 inhibitors has drawn investor attention, particularly after positive topline data in 2024.
52W Range: $19.58-$42.20
Congressional Interest in NewAmsterdam Pharma Company N.V. (NAMS)
No congressional trades have been disclosed for NewAmsterdam Pharma Company N.V. (NAMS) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading NAMS?
No congressional trades found for this stock.